Positive Press Coverage Somewhat Unlikely to Affect Tetralogic Pharmaceuticals Corp (TLOG) Stock Price

News stories about Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) have trended positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tetralogic Pharmaceuticals Corp earned a daily sentiment score of 0.38 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.1972301980242 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of Tetralogic Pharmaceuticals Corp (NASDAQ TLOG) traded up 23.123% during midday trading on Tuesday, hitting $0.041. The stock had a trading volume of 214 shares. The stock has a 50-day moving average of $0.03 and a 200 day moving average of $0.03. Tetralogic Pharmaceuticals Corp has a 52 week low of $0.02 and a 52 week high of $0.18. The stock’s market cap is $1.02 million.

COPYRIGHT VIOLATION NOTICE: “Positive Press Coverage Somewhat Unlikely to Affect Tetralogic Pharmaceuticals Corp (TLOG) Stock Price” was reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/10/10/positive-press-coverage-somewhat-unlikely-to-affect-tetralogic-pharmaceuticals-corp-tlog-stock-price.html.

Tetralogic Pharmaceuticals Corp Company Profile

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases.

Insider Buying and Selling by Quarter for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)

Receive News & Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply